162 related articles for article (PubMed ID: 21659624)
1. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J
J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
[TBL] [Abstract][Full Text] [Related]
5. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
[TBL] [Abstract][Full Text] [Related]
6. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
Hinneburg I
Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
[TBL] [Abstract][Full Text] [Related]
7. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
8. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
10. Disposition and mass balance of [14C]vernakalant after single intravenous and oral doses in healthy volunteers.
Mao ZL; Alak A; Wheeler JJ; Keirns J
Drug Metab Lett; 2011 Apr; 5(2):114-25. PubMed ID: 21457140
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
Stiell IG; Roos JS; Kavanagh KM; Dickinson G
Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
[TBL] [Abstract][Full Text] [Related]
12. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
Billman GE
Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
[TBL] [Abstract][Full Text] [Related]
13. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
[TBL] [Abstract][Full Text] [Related]
14. Vernakalant. Too dangerous in atrial fibrillation.
Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
[TBL] [Abstract][Full Text] [Related]
15. Vernakalant: RSD 1235, RSD-1235, RSD1235.
Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
[TBL] [Abstract][Full Text] [Related]
16. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
Tian D; Frishman WH
Cardiol Rev; 2011; 19(1):41-4. PubMed ID: 21135602
[TBL] [Abstract][Full Text] [Related]
17. Vernakalant hydrochloride to treat atrial fibrillation.
Brown RA; Lau YC; Lip GY
Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
[TBL] [Abstract][Full Text] [Related]
18. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
[TBL] [Abstract][Full Text] [Related]
19. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Hirt MN; Eschenhagen T
Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
[TBL] [Abstract][Full Text] [Related]
20. [Vernakalant for the conversion of atrial fibrillation of recent onset].
Seoane L; Baranchuk A; Conde D
Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
